TEM250117P29000
- 0.05
- 0.000.00%
Tempus AI Newsroom
Tempus AI Chairman and CEO Eric Lefkofsky Sells $62M of Shares
Investors Appear Satisfied With Tempus AI, Inc.'s (NASDAQ:TEM) Prospects As Shares Rocket 48%
Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways
Tempus AI Stock Before Q4 Earnings: To Buy or Not to Buy?
Tempus AI Insider Sold Shares Worth $62,023,231, According to a Recent SEC Filing
Stargate Project's Healthcare Winners: AI-led Biotechs and Metagenomi
Tempus AI Shares Are Trading Lower, Possibly Pulling Back From Strength Earlier in the Week.
Tempus AI, Inc (TEM): Driving Personalized Care With AI Amid Loom Capital's Revised $52 Target
Tempus AI has become Sister Wood's new favorite! Since 2025, more than 600,000 shares have been bought.
Since 2025, "Wood Lady" Cathie Wood's Ark Invest has significantly increased its holdings in Tempus AI, having bought over 600,000 shares since the beginning of the year.
Aiming for a 10-year extension! The AI pharmaceutical company invested by Altman is seeking to raise 1 billion dollars.
The biotechnology startup Retro Biosciences is conducting Series A financing to research projects that use AI technology to extend human lifespan. Previously, Altman had invested $0.18 billion in the seed round of financing for Retro Biosciences, and in this Series A financing, Altman will add further investment.
Tempus AI Options Spot-On: On January 23rd, 107.46K Contracts Were Traded, With 153.37K Open Interest
On January 23rd ET, $Tempus AI(TEM.US)$ had active options trading, with a total trading volume of 107.46K options for the day, of which put options accounted for 28.56% of the total transactions,
Cathie Wood Goes All in on Tempus AI, Boosting Holdings by Over 600K Shares in 2025
The chairman of Oracle promotes AI-driven mRNA vaccines, and AI drug developers respond with a surge, with Moderna rising over 7%.
Larry Ellison stated that AI can be used to develop personalized cancer vaccines based on mRNA and for early tumor detection.
(SEC Amendment) Tempus AI(TEM.US) 10% Shareholder Sells US$33.14 Million in Common Stock
$Tempus AI(TEM.US)$ 10% Shareholder KEYWELL BRADLEY A sold 946.08K shares of common stock on Jan 15, 16, 17, 2025 at an average price of $35.0251 for a total value of $33.14 million.Source:
Why Tempus AI, Inc (TEM) Soared At The Start Of The Trading Week
Moderna Spikes as Oracle's Larry Ellison Touts AI-driven MRNA Vaccines
Daily short sale tracking: Lucid Group's short volume increased by 6 million, with a short sale ratio of 15%
Lucid Group(LCID.US) ranked top of the list had the largest change in short volume (6.05 million shares), and the short volume ratio of Magnolia Oil & Gas(MGY.US) reached 50.47%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Tempus AI surged by 35% after being targeted by the "Congressional Stock God"! What other "AI + Medical" Stocks are worth paying attention to?
After CES 2025, Goldman Sachs released Research Reports highlighting several key themes and companies in the pharmaceutical and health Industry: Abbott Laboratories, Teladoc Health, and iRhythm Technologies are well positioned.
Tempus AI surged more than 16% in after-hours trading! It received a major bet from the 'Stock God of Capitol Hill'. What is the background of this company?
Since Pelosi bought Call Options, the stock price of Tempus AI has risen nearly 50%. Tempus AI focuses on applying AI technology in the field of precision medicine and launched an AI-driven personal health assistant application on Tuesday.
Express News | U.S. stock night market: Pelosi's "new love" Tempus AI continues to rise over 19%, Netflix surged more than 14% after earnings.